

Ensemble Therapeutics Presents Data at American Chemical Society National Meeting

-- Progress with Macrocyclic-Based Drug Discovery Platform Highlighted --

CAMBRIDGE, MA - August 23, 2010 – [Ensemble Therapeutics](#) announced today the presentation of data on its macrocyclic-based drug discovery platform at the [American Chemical Society \(ACS\) National Meeting](#) August 22-26, in Boston at the Boston Convention and Exposition Center.

Poster Presentations:

- #222: Tuesday, August 24, 2010, 5:30 p.m., “The Rapid Creation and Selection of Macrocyclic Libraries for the Modulation of Protein-Protein Interactions”, Connors, et.al., Exhibit Hall C.
- #667: Tuesday, August 24, 2010, 8:00 p.m., Division of Organic Chemistry, “The Rapid Creation and Screening of Peptidic-Macrocyclic Libraries against Protein-Protein Interactions”, Yan, et.al., Exhibit Hall C.
- #429: Wednesday, August 25, 2010, 7:00 p.m., Division of Medicinal Chemistry, “Drug-Like Properties Of Macrocyclic Molecules Derived From DNA-Programmed Combinatorial Libraries”, Seigal, et.al., Ballroom.

Special Oral Presentation:

- #62: Young Investigators Symposium, Sunday, August 22, 2010, 9:15 a.m. “DNA-Programmed Chemistry Approaches To Macrocyclic Lead Compounds”, Fraley, et.al., Room 205A/B. This symposium highlights up-and-coming investigators who have demonstrated outstanding promise for future contributions to Organic Chemistry.

“The body of data presented at ACS this year demonstrates Ensemble’s progress in deploying our proprietary DNA-programmed drug discovery platform to assess large numbers of macrocycles with the goal of rapidly optimizing lead drug candidates for development of novel macrocycle-based therapeutics,” said Dr. [Michael D. Taylor](#), CEO of Ensemble Therapeutics. “With their unique macrocyclic structure, Ensemblins are a new class of orally-active drugs with unique properties for binding to a large number of historically challenging human disease targets.”

About Ensemblins

[Ensemblins™](#) are a new class of synthetic [macrocycles](#) developed by Ensemble using its proprietary chemistry platforms, including [DNA-Programmed Chemistry™](#). Macrocylic rings are found in many natural product-based drugs and bestow favorable pharmaceutical properties and powerful protein surface binding properties upon such drugs. Thus, macrocycles are uniquely suited to address many protein targets that cannot be modulated effectively by traditional small molecule pharmaceutical compounds. Macrocycles have been challenging to synthesize in large numbers and this has constrained their wider use in the industry. Ensemble has produced larger collections of macrocyclic drug candidates than any previously synthesized in the pharmaceutical industry.

About Ensemble Therapeutics

Based in Cambridge, MA, [Ensemble Therapeutics](#) is deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as "[Ensemblins](#)". Ensemble is the exclusive worldwide licensee from Harvard University of its patents covering [DNA-Programmed Chemistry](#).

Ensemble is pursuing a proprietary drug pipeline and also collaborations with pharmaceutical partners. Ensemble has two drug discovery alliances with Bristol-Myers Squibb (April 2009) and Pfizer (January 2010). Ensemble's lead proprietary programs are in the inflammatory disease field. For more information, visit: www.ensembletx.com.

Media Contact:
Gina Nugent
The Yates Network
617-460-3579